In brief
- Who may benefit: adults with severe primary axillary hyperhidrosis, after secondary causes have been assessed and topical treatments have not been sufficient.
- How it works: it temporarily reduces the nerve signal that activates sweat glands in the injected area.
- When it starts: many patients notice less sweating in about 7 to 10 days.
- How long it lasts: this varies. The AAD patient guide gives a typical range of about 3 to 10 months for underarms; the median response in BOTOX registration trials was 201 days.
- Safety: local discomfort is common, but all botulinum toxin products carry a warning about the rare possibility of effects spreading and impairing swallowing or breathing.
- Regulation: the approval and dose information below comes from the U.S. BOTOX label. In Mexico, the current registration of the exact brand and presentation must be checked with COFEPRIS.
Botox in the underarms for hyperhidrosis: a patient guide
Hyperhidrosis is excessive sweating that can interfere with clothing, work, sleep, and social life. When it mainly affects the underarms and is not caused by another condition or medication, it is called primary axillary hyperhidrosis.
OnabotulinumtoxinA, marketed as BOTOX®, is an established option for severe cases that are not adequately controlled by topical treatment. “Botox” is a brand, not the name of every botulinum toxin: each product has its own indications, dose, and units.
What is hyperhidrosis?
Sweating is a normal function that helps regulate temperature. Hyperhidrosis means sweating is excessive for the body’s needs and disrupts daily life.
Excessive sweating may occur without an identifiable cause or result from another condition, such as a thyroid disorder, low blood sugar, menopause, infection, or certain medications. Generalized or nighttime sweating, a recent onset, or sweating with other symptoms should be medically evaluated before only the underarms are treated.
Primary and secondary hyperhidrosis
Primary focal hyperhidrosis is often bilateral and fairly symmetric, frequently begins in younger people, and may run in families. Secondary hyperhidrosis is related to a medical condition or medication and may follow a different pattern.
These features are clues, not a diagnosis by themselves. A clinician may review symptoms, medicines, and medical history, perform an examination, and order tests when appropriate.
The HDSS scale
The Hyperhidrosis Disease Severity Scale (HDSS) is a short scale describing how much sweating interferes with daily activities:
- It is never noticeable and never interferes.
- It is tolerable but sometimes interferes.
- It is barely tolerable and frequently interferes.
- It is intolerable and always interferes.
The U.S. BOTOX label defines the indication as severe primary axillary hyperhidrosis that is inadequately managed with topical agents. Severity, diagnosis, and previous treatment therefore matter before deciding.
How does botulinum toxin work in the underarms?
Sweat glands receive a nerve signal through acetylcholine. OnabotulinumtoxinA temporarily blocks its release in the treated area and reduces sweat production.
The injection is intradermal, meaning it is placed in the skin rather than in muscle as in many cosmetic uses. The effect is local and temporary. It controls a symptom but does not cure an underlying cause of secondary sweating.
How effective is it?
Results must be interpreted using each study’s definition of response.
In one trial included in the BOTOX prescribing information, 55% of treated participants improved by at least two HDSS grades, compared with 6% given placebo. In another study, 91% had at least a 50% reduction in sweat production at four weeks, compared with 36% given placebo.
The median response after the first treatment was 201 days. Among people who received a second treatment, the median was similar, not progressively longer. Some people respond for less time and others for longer; an individual interval cannot be promised.
When does it begin to work?
The AAD says most patients notice less sweating within 7 to 10 days. Timing varies, so the result should not be judged only during the first few days.
The plan is product- and patient-specific
Dose, number of sites, and distribution must be determined from the applicable label, extent of sweating, anatomy, medical history, and examination. Those decisions belong with the treating professional and are not self-injection instructions.
BOTOX Units cannot be reliably compared with or converted to Dysport, XEOMIN, or other botulinum toxin units. A regimen for one brand or indication should not be transferred to another.
Mexico and product authenticity
An FDA approval describes U.S. regulatory status; it does not establish authorization in Mexico. In Mexico, the current COFEPRIS registry should be checked for the exact brand, presentation, authorization holder, and indication.
COFEPRIS has also published alerts about counterfeit BOTOX presentations. Treatment should use authentic, traceable product obtained through authorized channels. A patient can ask to see the packaging, lot, and registration.
What happens during the procedure?
The consultation begins by confirming the diagnosis and reviewing previous treatments, medications, allergies, and medical history.
The clinician may use an iodine-starch test to map the area of greatest sweating. Multiple points are then marked and small intradermal injections are given. The BOTOX prescribing information describes a fine needle and an even distribution; the final technique belongs to a trained clinician.
Most people feel a series of brief pinpricks. Cold or topical anesthetic may be used depending on sensitivity and clinical judgment. Aftercare varies by patient and practice, so follow the instructions given by the treating clinician.
Do not stop aspirin, an anticoagulant, or any prescribed medicine on your own. Disclose everything you take and agree on any change with the clinician who prescribed it.
Other treatment options
There is no single ideal treatment for everyone. The plan depends on the cause, body area, severity, preferences, and prior response.
- Antiperspirants: these are often the first step and may contain aluminum chloride. Skin irritation can occur.
- Prescription topical medicines: anticholinergic cloths or gels are authorized in some countries; availability and approval differ.
- Iontophoresis: used mainly for hands and feet. Underarm attachments exist, but the method tends to work less well there.
- Oral medicines: these may reduce sweating but can cause dry mouth, blurred vision, constipation, difficulty urinating, and a greater risk of overheating.
- Energy-based treatment or sweat-gland removal: these can have longer-lasting effects, with their own risks and costs.
- Sympathetic nerve surgery: reserved for selected cases that have not responded to other treatment because it can cause permanent compensatory sweating and other complications.
Botulinum toxin is one option among several, not a universally “best” solution.
Side effects, precautions, and urgent symptoms
Adverse effects seen in axillary-hyperhidrosis studies include injection-site pain or minor bleeding, sweating outside the underarms, itching, infection, headache, and flu-like symptoms. Not everyone experiences them.
Important warning
The prescribing information carries a boxed warning: toxin effects can spread beyond the injection area hours to weeks later. Seek urgent medical care for difficulty breathing, speaking, or swallowing; generalized weakness; double vision; or marked eyelid drooping.
Who should not receive it?
The formal BOTOX contraindications include:
- a known allergy to any botulinum toxin preparation or its ingredients;
- infection at the proposed injection site.
Neuromuscular disorders, existing swallowing or breathing problems, and some medicines are not all automatic “contraindications,” but they can increase risk and require assessment. Disclose aminoglycoside antibiotics, muscle relaxants, another botulinum toxin product, and anything else that may affect neuromuscular transmission.
There are not adequate data to define risk during pregnancy or breastfeeding. Because this is usually an elective treatment, it should be discussed individually and is commonly postponed when there is no clear medical need.
Sources
- Comisión Federal para la Protección contra Riesgos Sanitarios. Listados de Registros Sanitarios de Medicamentos. https://www.gob.mx/cofepris/documentos/registros-sanitarios-medicamentos
- Comisión Federal para la Protección contra Riesgos Sanitarios. Alertas sanitarias de medicamentos. https://www.gob.mx/cofepris/documentos/alertas-sanitarias-de-medicamentos
- AbbVie. BOTOX (onabotulinumtoxinA) Prescribing Information. https://www.rxabbvie.com/pdf/botox_pi.pdf
- U.S. Food and Drug Administration. BOTOX (onabotulinumtoxinA) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103000orig1s5325correctedlbl.pdf
- American Academy of Dermatology. Hyperhidrosis: diagnosis and treatment. https://www.aad.org/public/diseases/a-z/hyperhidrosis-treatment
- American Academy of Dermatology. Botulinum toxin therapy: FAQs. https://www.aad.org/public/cosmetic/wrinkles/botulinum-toxin-faqs
- Mayo Clinic. Hyperhidrosis: diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/hyperhidrosis/diagnosis-treatment/drc-20367173
- MedlinePlus. OnabotulinumtoxinA injection. https://medlineplus.gov/druginfo/meds/a608013.html
- NHS. Excessive sweating (hyperhidrosis). https://www.nhs.uk/conditions/excessive-sweating-hyperhidrosis/
Reviewed by our medical team
Dra. Jessica Tapia
Medical Director
Clinical content on this blog is reviewed by the Juvenalia Brío medical team for scientific accuracy and consistency with the care we provide.
